- Home
- CIFR vs MRUS Comparison
CIFR vs MRUS Comparison
Compare CIFR & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- MRUS
- Stock Information
- Founded
- CIFR 2021
- MRUS 2003
- Country
- CIFR United States
- MRUS Netherlands
- Employees
- CIFR N/A
- MRUS N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- MRUS Health Care
- Exchange
- CIFR Nasdaq
- MRUS Nasdaq
- Market Cap
- CIFR 5.6B
- MRUS 5.1B
- IPO Year
- CIFR N/A
- MRUS 2016
- Fundamental
- Price
- CIFR $17.44
- MRUS $94.38
- Analyst Decision
- CIFR Strong Buy
- MRUS Buy
- Analyst Count
- CIFR 10
- MRUS 18
- Target Price
- CIFR $12.61
- MRUS $93.72
- AVG Volume (30 Days)
- CIFR 55.1M
- MRUS 4.2M
- Earning Date
- CIFR 10-30-2025
- MRUS 10-30-2025
- Dividend Yield
- CIFR N/A
- MRUS N/A
- EPS Growth
- CIFR N/A
- MRUS N/A
- EPS
- CIFR N/A
- MRUS N/A
- Revenue
- CIFR $158,849,000.00
- MRUS $56,228,000.00
- Revenue This Year
- CIFR $81.77
- MRUS $47.25
- Revenue Next Year
- CIFR $67.84
- MRUS N/A
- P/E Ratio
- CIFR N/A
- MRUS N/A
- Revenue Growth
- CIFR 0.11
- MRUS 59.77
- 52 Week Low
- CIFR $1.86
- MRUS $33.19
- 52 Week High
- CIFR $18.09
- MRUS $94.56
- Technical
- Relative Strength Index (RSI)
- CIFR 72.66
- MRUS 86.42
- Support Level
- CIFR $14.33
- MRUS $66.13
- Resistance Level
- CIFR $16.12
- MRUS $94.39
- Average True Range (ATR)
- CIFR 1.35
- MRUS 1.11
- MACD
- CIFR 0.14
- MRUS 1.89
- Stochastic Oscillator
- CIFR 88.63
- MRUS 99.47
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.